Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update Jul 28, 2021 04:05PM
Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021 Jul 21, 2021 04:05PM
Viking Therapeutics (VKTX) Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD Jun 24, 2021 07:06AM
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD Jun 24, 2021 07:05AM
Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214 Jun 17, 2021 07:05AM
View Older Stories

Jun 17, 2021 07:05AM Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214
Jun 10, 2021 04:05PM Viking Therapeutics to Participate in Upcoming Investor Conferences
Apr 28, 2021 04:05PM Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
Apr 21, 2021 04:05PM Viking Therapeutics to Report Financial Results for First Quarter 2021 on April 28, 2021
Apr 7, 2021 04:05PM Viking Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
Mar 4, 2021 04:30PM Viking Therapeutics to Participate at Upcoming Investor Conferences
Feb 17, 2021 04:05PM Viking Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
Feb 10, 2021 04:05PM Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2020 on February 17, 2021
Jan 6, 2021 04:05PM Viking Therapeutics Announces Senior Management Team Appointments
Jan 5, 2021 04:05PM Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference
Nov 10, 2020 04:05PM Viking Therapeutics to Present at Stifel Healthcare Conference 2020
Oct 28, 2020 04:05PM Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Oct 21, 2020 04:05PM Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020
Sep 9, 2020 07:09AM Viking Therapeutics (VKTX) Begins Phase 1 Clinical Trial of VK0214
Sep 9, 2020 07:05AM Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214
Sep 2, 2020 04:30PM Viking Therapeutics to Participate in Upcoming Investor Conferences
Aug 28, 2020 06:05AM Viking Therapeutics (VKTX) Highlights New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
Aug 28, 2020 06:00AM Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congressâ„
Aug 20, 2020 07:34AM Viking Therapeutics (VKTX) to Present New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol at The Digital International Liver Congress 2020
Aug 20, 2020 07:30AM Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress
Jul 29, 2020 04:05PM Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 28, 2020 04:05PM Viking Therapeutics to Participate in Upcoming Investor Conferences
Jul 22, 2020 04:05PM Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020
May 27, 2020 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
May 12, 2020 05:00PM Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
Apr 30, 2020 04:05PM Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Apr 28, 2020 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
Apr 23, 2020 07:30AM Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020
Apr 7, 2020 07:30AM Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference
Feb 26, 2020 04:15PM Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
Feb 24, 2020 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
Feb 19, 2020 07:30AM Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2019 on February 26, 2020
Jan 6, 2020 07:30AM Viking Therapeutics to Present at Biotech Showcase 2020
Nov 19, 2019 07:06AM Viking Therapeutics (VKTX) Begins Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis
Nov 19, 2019 07:05AM Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Nov 5, 2019 07:00AM Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 31, 2019 07:30AM Viking Therapeutics to Report Financial Results for Third Quarter 2019 on November 5, 2019
Sep 25, 2019 07:30AM Viking Therapeutics to Present at 2019 Cantor Global Healthcare Conference
Aug 28, 2019 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
Aug 1, 2019 04:05PM Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 25, 2019 04:05PM Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
Jul 2, 2019 04:05PM Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
May 28, 2019 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
May 2, 2019 04:05PM Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Apr 30, 2019 07:30AM Viking Therapeutics to Participate in Upcoming Investor Conferences
Apr 25, 2019 07:30AM Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
Apr 11, 2019 07:03AM Viking Therapeutics (VKTX) Presents New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol at EASL
Apr 11, 2019 07:02AM Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Apr 4, 2019 07:32AM Viking (VKTX) to Present New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol
Apr 4, 2019 07:30AM Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
View Older Stories